⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195358 | 0.74 | — | — | |
| SCHEMBL10761177 | 0.72 | — | — | |
| SCHEMBL27881631 | 0.72 | — | — | |
| SCHEMBL123396 | 0.72 | — | — | |
| SCHEMBL7736489 | 0.72 | — | — | |
| SCHEMBL10364271 | 0.72 | — | — | |
| SCHEMBL13350497 | 0.72 | — | — | |
| SCHEMBL9430418 | 0.72 | — | — | |
| SCHEMBL24414545 | 0.69 | — | — | |
| SCHEMBL1986762 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970485-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2024-04-30 | — | — | US | claimed |
| US-11964968-B2 | Compounds useful for inhibiting RET kinase | ELI LILLY AND COMPANY (US) | 2024-04-23 | — | — | US | claimed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | claimed |
| US-20230312544-A1 | COMPOUNDS USEFUL FOR INHIBITING RET KINASE | LOXO ONCOLOGY, INC. | 2023-10-05 | — | — | US | claimed |
| US-20230265085-A1 | RET KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-08-24 | — | — | US | claimed |
| US-11697647-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2023-07-11 | — | — | US | claimed |
| US-11613533-B2 | Compounds useful for inhibiting RET kinase | ELI LILLY AND COMPANY (US) | 2023-03-28 | — | — | US | claimed |
| EP-4143184-A1 | COMPOUNDS USEFUL FOR INHIBITING RET KINASE | Eli Lilly and Company (US) | 2023-03-08 | — | — | EP | claimed |
| US-20220144816-A1 | RET KINASE INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | claimed |
| US-20210363140-A1 | COMPOUNDS USEFUL FOR INHIBITING RET KINASE | LOXO ONCOLOGY, INC. | 2021-11-25 | — | — | US | claimed |
| EP-2352723-B1 | PESTICIDAL N-ARYL- OR N-HETEROARYL PYRAZOLE CARBOXAMIDE COMPOUNDS | BAYER IP GMBH (DE) | 2016-11-23 | — | — | EP | claimed |
| EP-2705049-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-19 | — | — | EP | claimed |
| US-8962608-B2 | Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-24 | — | — | US | claimed |
| US-8957203-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-17 | — | — | US | claimed |
| US-20140243309-A1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-28 | — | — | US | claimed |
| EP-2705049-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-03-12 | — | — | EP | claimed |
| WO-2012151195-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-08 | — | — | WO | claimed |
| CN-101341127-A | 4,5-dihydro- (1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | SOLVAY PHARM BV (NL) | 2009-01-07 | — | — | CN | claimed |
| US-20080312276-A1 | 4,5 Dihydro-(1H)-Pyrazole Derivatives as Cannabinoid CB1 Receptor Modulators | SOLVAY PHARMACEUTICALS, B.V. | 2008-12-18 | — | — | US | claimed |
| US-20070142362-A1 | 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | SOLVAY PHARMACEUTICALS B.V. | 2007-06-21 | — | — | US | claimed |